To include your compound in the COVID-19 Resource Center, submit it here.

Azixa verubulin: Phase II data

A Phase II trial in 31 patients with recurrent GBM naïve to treatment with bevacizumab showed that once-weekly 3.3 mg/m

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE